Angiogenesis as a biomarker and target in cancer chemoprevention

Lancet Oncology

Volumn 2, Issue 12, 2001, Pages 726-732

  Sharma, Ricky A ^a   Harris, Adrian L ^b   Dalgleish, Angus G ^c   Steward, William P ^a   O'Byrne, Kenneth J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; GROWTH FACTOR;

ANGIOGENESIS; ASSAY; BIOCHEMISTRY; BLOOD VESSEL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DISEASE MARKER; ENDOSCOPY; FLUORESCENCE; HISTOPATHOLOGY; IN VIVO STUDY; INFECTION; INFLAMMATORY DISEASE; INHIBITION KINETICS; MALIGNANT TRANSFORMATION; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; VALIDATION PROCESS; VASCULARIZATION;

EID: 0035206981     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00586-1     Document Type: Review

References (75)

1. Heterologous transplantation of mammalian tumors. The transfer of human tumors to alien species
2. Clinical applications of research on angiogenesis
3. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis
4. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
5. The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: A quantitative histological study
6. Intratumoral angiogenesis: A new prognostic indicator for stage I endometrial adenocarcinomas?
7. Tumor angiogenesis, apoptosis and p53 oncogene in stage I lung adenocarcinoma
8. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-call lung cancer
9. Expression of P53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer
10. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
11. Angiogenesis and neoplastic progression in vitro
12. Vascularization of premalignant lesions in carcinogen-treated hamster cheek pouch
13. Expression of angiogenic phenotype by a subpopulation of keratinocytes derived from 7, 12-dimethylbenz[a]anthracene-initiated hamster buccal pouch epithelium
14. Angiogenesis as a marker of preneoplastic lesions of the human breast
15. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder
16. Endothelial proliferation in the delayed hypersensitivity reaction: An autoradiographic study
17. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
18. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia
19. Neovascularisation in hyperplastic, metaplastic and potentially preneoplastic lesions of the bronchial mucosa
20. Modulation of neoangiogenesis in bronchial preneoplastic lesions
21. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast
22. Angiogenesis in the neoplastic sequence of Barrett's oesophagus: Correlation with VEGF expression
23. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer
24. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis
25. Angiogenesis is an early event in the development of chemically induced skin tumors
26. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis
27. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the cirrhotic liver
28. Molecular pathobiology and immunology of malignant mesothelioma
29. Irregular regeneration of hepatocytes and the risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection
30. Angiogenic properties of human immunodeficiency virus type 1 Tat protein
31. G-protein coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
32. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis
33. Previous lung disease and risk of lung cancer among men and women nonsmokers
34. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease
35. Oncogenes as inducers of tumor angiogenesis
36. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis
37. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
38. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma
39. Serum vascular endothelial growth factor levels in various liver diseases
40. Expression of vascular endothelial growth factor in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis
41. Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis
42. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development
43. Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis
44. The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFβ-1 and is unaffected by ras activation
45. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
46. Platelet-derived endothelial cell growth factor expression and angiogenesis and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix
47. Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma
48. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas: A molecular and immunohistochemical study
49. Synergistic induction of cyclooxygenase-2 by transforming growth factor-betal and epidermal growth factor inhibits apoptosis in epithelial cells
50. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas
51. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis
52. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung
53. Cyclooxygenase 2 is upregulated and localized to macrophages in the intestine of Min mice
54. Activated macrophages induce vascular proliferation
55. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer
56. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast
57. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer
58. Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinae-2 levels in p53-mutated human melanoma cells
59. Angiogenic factor VEGF is decreased in human colorectal neoplasms showing DNA microsatellite instability
60. Colorectal cancer chemoprevention: Biochemical targets and clinical development of promising agents
61. Cancer chemoprevention by dietary constituents: A salutary tale of failure and promise
62. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
63. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
64. Do inhibitors of angiotensin-I-converting enzyme protect against the risk of cancer?
65. Overexpression of the wild-type p53 gene inhibites NF-kappa B activity and synergizes with aspirin to induce apoptosis in human colon cancer cells
66. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
67. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis
68. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake
69. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis
70. Inhibition of angiogenesis as a mechanism for inhibition by 1-alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats
71. Curcumin is an in vivo inhibitor of angiogenesis
72. Rationale for use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer
73. Angiogenesis inhibited by drinking tea
74. Elevated matrix metalloprotease and angiostatin levels in integrin alfa 1 knockout mice cause reduced tumor vascularization
75. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials